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Pseudomonas aeruginosa and the Burkholderia cepacia complex represent very
problematic cystic ﬁbrosis pathogens with innate multidrug resistance. We in-
vestigated antimicrobial resistance in these pathogens, speciﬁcally focusing on
biocide resistance. Biocides such as chlorhexidine and cetylpyridinium chloride
are widely used for disinfection of the hospital and home environments. Biocide
resistance was determined for panels of representative P. aeruginosa and B. cepacia
complex strains (23 and 81 strains, respectively). Strains were chosen based on
their Multilocus Sequence Type and clinical background such as transmissibility.
Minimum inhibitory concentrations (MICs) for chlorhexidine and cetylpyridinium
chloride were determined using broth dilution assays. B. cenocepacia was signiﬁ-
cantly more resistant to chlorhexidine than other species within the complex (mean
MIC= 54.5mg/ml). P. aeruginosa strains had signiﬁcantly lower chlorhexidine
resistance (mean MIC= 18.64mg/ml) than B. cenocepacia strains. No correlation
between biocide resistance and antibiotic resistance was observed; E.g, the B. dolosa
strain LMG 18943 had low resistance to chlorhexidine (25mg/ml), but was resistant
to all ten antibiotics tested. A microarray experiment was carried out to determine
what genes are expressed by B. cenocepacia J2315 in response to exposure to
chlorhexidine. Signiﬁcant up-regulation of expression was seen in: (i) multidrug
efﬂux pump genes; (ii) LPS biosynthesis genes; and (iii) protein secretion genes;
ﬂagellar biosynthesis genes were down-regulated.
This research was funded by grants from the Big Lottery Fund and the UK Cystic
Fibrosis Trust.
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Background: Photodynamic therapy (PDT) combines a photosensitizer dye with
visible light to excite the dye to generate reactive oxygen radicals toxic to cells. The
emergence of antibiotic resistance in Pseudomonas aeruginosa (PA) CF isolates
highlights the need for alternative treatment strategies. This study is aimed to
evaluate the in-vitro effect of PDT alone and in the presence of antibiotics on
CF PA isolates.
Methods: PA ATCC 27853, PAOmutS and 4 CF PA isolates were tested for
susceptibility against ceftazidime (CAZ), meropenem (MEM), amikacin (AK) and
ciproﬂoxacin (CIP) by microdilution method. PDT was applied by using toluidine
blue at a light dose of 70 joule/cm2 with a light emitting diode and light mediated
killing was determined by viable cell counts. PDT was also applied on antibiotic
containing MIC trays and effect on MIC values were tested. MBC values were
determined by direct plate count for MIC and MIC+PDT trays.
Results: PDT alone exhibited 2 log killing in 3, 1 log in one and no effect
in 2 strains. PDT application in presence of antibiotics lowered the MIC values
signiﬁcantly except for MEM. PDT application in the presence of AK and CIP
decreased viable cell counts at least 3 logs for all the strains. PDT+CAZ and
PDT+MEM achieved bactericidal activity in half of the strains.
Conclusions: Although PDT alone was not able to achieve bactericidal concentra-
tions for all the tested strains, a signiﬁcant bactericidal effect was detected when
PDT was applied in the presence of antibiotics. Resistance to antibiotics in CF PA
isolates may be overcome by the synergistic activity of PDT which should further
be improved for in-vivo application.
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Introduction and Aims: Photodynamic antimicrobial chemotherapy (PACT), in
which a combination of a photosensitiser and visible light cause selective destruction
of microbial cells could be a potential alternative method for treatment of chronic
Cystic Fibrosis (CF) pulmonary infection caused by bacteria such as P. aeruginosa.
The aim of this in vitro study was, therefore, to investigate the potential use of
PACT in the treatment of P. aeruginosa CF pulmonary infection.
Methods: The diffusion of two photosensitisers (toluidine blue O [TBO]) and meso-
tetra (N-methyl-4-pyridyl) porphine tetra tosylate (TMP) and light across artiﬁcial
mucus was determined using a modiﬁed Franz cell and a light detector, respectively.
The susceptibility of clinical P. aeruginosa isolates growing both planktonically and
in bioﬁlm to PACT was determined using microtitre tray assays.
Results: Red light (635 nm) and both TBO and TMP were delivered successfully
across artiﬁcial CF mucus with similar concentrations of both photosensitisers
achieved in the receiver compartment to those required to achieve high rates of
kill (>99%) of P. aeruginosa isolates growing both planktonically and in bioﬁlms.
TMP required signiﬁcantly higher concentrations (2.5mg/ml) than TBO to achieve
high rates of kill (>99%) of P. aeruginosa isolates growing planktonically. Higher
concentrations (5.0mg/ml) of both photosensitisers were required to achieve high
rates of kill (>99%) of P. aeruginosa isolates growing in bioﬁlms.
Conclusion: PACT is capable of achieving high levels of kill of clinical P. aerugi-
nosa isolates growing both planktonically and in bioﬁlm.
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Tigecycline is a new injectable glycylcycline antibiotic related to minocycline. It has
in-vitro activity against non-fermentative Gram negative bacteria (excluding Pseu-
domonas aeruginosa), Staphylococcus aureus (including MRSA), Haemophilus
inﬂuenzae, and rapid-growing non-tuberculous mycobacteria. We report our early
experiences of using it to treat difﬁcult respiratory pathogens in cystic ﬁbrosis (CF).
Since June 2006 we have treated six patients with CF with intravenous tigecycline
(four adults, two children aged 12 and 16) using a 100mg loading dose followed
by 50mg twice daily. The targeted pathogens were Burkholderia cepacia complex,
Pandoraea apista, Stenotrophomonas maltophilia, Mycobacterium abscessus, and
M. chelonae. Treatment options in all six cases were limited by multi-resistance
and/or allergy to conventional therapies. Two patients discontinued tigecycline early
(after ﬁve and seven days, respectively) because of nausea and vomiting. The other
four patients tolerated the drug after they were given prophylactic anti-emetics,
with courses ranging from 11 to 33 days. All four showed evidence of clinical
response, although co-adminstration of other therapies (mainly beta-lactams and
aminoglycosides) may also have contributed to this. Tigecycline is a promising
addition to the often-limited treatment options available for these pathogens, but
uncertainty over stability have prevented its use outside of the in-patient setting.
Properly constructed trials are required to ascertain its true clinical value.
